1

Avalo Therapeutics

Avalo Therapeutics
Leadership team

Dr. Garry A. Neil M.D. (Chairman, Pres & CEO)

Dr. Solomon H. Snyder M.D. (Founder and Chairman of Scientific Advisory Board)

Dr. Barbara S. Slusher Ph.D. (Founder and Member of Scientific Advisory Board)

Products/ Services
Biotechnology, Therapeutics
Number of Employees
0 - 50
Headquarters
Rockville, Maryland, United States
Established
2011
Company Registration
SEC CIK number: 0001534120
Revenue
5M - 20M
Traded as
NASDAQ:AVTX
Social Media
Overview
Location
Summary
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
History

Avalo Therapeutics was founded in 2015 with a mission to develop novel therapeutics based on immune cell–directed gene technology. Since then, Avalo has developed a broad portfolio of innovative therapies across multiple disease areas such as oncology, autoimmune diseases, infectious diseases and more.

Mission
Our mission is to translate novel biological insights into novel therapies for the treatment of cancer and other serious diseases with a focus on delivering novel and safe immunotherapies.
Vision
Avalo Therapeutics’ vision is to be the leader in the development of innovative immune-based therapies for the treatment of cancer and other serious diseases.
Key Team

Mr. Christopher Ryan Sullivan (Chief Financial Officer)

Dr. Lisa Hegg Ph.D. (Sr. VP of Program Management & Corp. Infrastructure)

Ms. Colleen Matkowski (Sr. VP of Global Regulatory Affairs & Quality Assurance)

Mr. Maxim Jacobs C.F.A. (VP of Investor Relations)

Dr. Dino C. Miano Ph.D. (Sr. VP of CMC & Technical Operations)

Dr. Stephen Thomas Ph.D. (VP & Head of Discovery)

Dr. Blake M. Paterson M.D. (Scientific Advisor)

Recognition and Awards
Avalo has received numerous awards and recognition including the Innovator of the Year Award from the Massachusetts Biotechnology Council, the Global Biotech Impact Award from the International Society for Cell & Gene Therapy, and the Activator Award from the Global Biotech Revolution.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Avalo Therapeutics
Leadership team

Dr. Garry A. Neil M.D. (Chairman, Pres & CEO)

Dr. Solomon H. Snyder M.D. (Founder and Chairman of Scientific Advisory Board)

Dr. Barbara S. Slusher Ph.D. (Founder and Member of Scientific Advisory Board)

Products/ Services
Biotechnology, Therapeutics
Number of Employees
0 - 50
Headquarters
Rockville, Maryland, United States
Established
2011
Company Registration
SEC CIK number: 0001534120
Revenue
5M - 20M
Traded as
NASDAQ:AVTX
Social Media